I wonder what this means? NICE is the UKs assessment system for drugs to be used in the NHS. Looks like both fostemsavir and Trogarzo are going thru the process together. They both got the same outcome from a Nov 2020 meeting.
"Oversight Panel concluded that an appraisal of ibalizumab in combination with other antiretroviral treatment for multidrug-resistant HIV-1 would be of limited value to the NHS at this time and therefore the topic will not progress any further"
It sounds pretty negative but I can't believe both drugs are being blocked for use in the NHS so it must just mean there is nothing to be gained from further talking. What you think? Could there be a UK decision soon? Be interesting if both drugs become available together. Might we get a culture of double switching in UK?
https://www.nice.org.uk/guidance/proposed/gid-ta10657
https://www.nice.org.uk/guidance/proposed/gid-ta10605